R&D Trends

Celtic launches $50 million antibody drug conjugates company

Monday, March 26, 2012 12:19 PM

Celtic Therapeutics Management, a global private equity firm focused on novel therapeutic product candidates, has announced a significant commitment to Antibody-Drug-Conjugate (ADC) products with the launch of a new Lausanne, Switzerland-based company, ADC Therapeutics Sarl.

More... »

Report: U.K. a leader in dementia research

Thursday, March 22, 2012 02:56 PM

The quality of dementia research in the U.K. is second only to the U.S., despite the low number of scientists working in this field, and finding a cure can be accelerated by increasing the number of dementia researchers and investment, according the Intellectual Property & Science business of Thomson Reuters. The findings are featured in an Alzheimer’s U.K. research report “Defeating Dementia.”

More... »

Wellcome Trust to launch $317 million investment business

Wednesday, March 21, 2012 10:36 AM

The Wellcome Trust’s board of governors has approved the creation of a new business that will invest in emerging businesses and technologies in the healthcare and life sciences sectors.

More... »

Rx&D and Canadian government partner to strengthen research

Wednesday, March 21, 2012 09:39 AM

Canada’s Research Based Pharmaceutical Companies (Rx&D) and the Canadian Institutes of Health Research (CIHR) have renewed a partnership to strengthen clinical research done in Canada, announced Leona Aglukkaq, Minister of Health.

More... »

Index Ventures launches $198 million life sciences fund

Wednesday, March 21, 2012 09:26 AM

Index Ventures, a venture capital firm, has launched its first fund solely dedicated to making investments in the life sciences sector.

More... »

Academic-industry collaboration seeks new drugs, treatments for autism

Monday, March 19, 2012 02:41 PM

An international consortium of scientists led by Roche, King's College London and Autism Speaks is collaborating on one of the largest ever academic-industry research projects, to find new methods for the development of drugs for autism spectrum disorder (ASD), which affects 1% of children worldwide.

More... »

ViroPharma contracts Recipharm to manufacture Plenadren

Monday, March 19, 2012 09:56 AM

Recipharm, the international contract pharmaceutical development and manufacturing organization, has been contracted by ViroPharma to complete commercial scale-up manufacture of Plenadren (hydrocortisone), used for the treatment of adrenal insufficiency in adults.

More... »

Sanofi acquires Pluromed, expands presence in biosurgery

Friday, March 16, 2012 04:12 PM

Sanofi has entered into an agreement with Pluromed to acquire the medical device company based in Woburn, Mass.

More... »

Shire to acquire FerroKin BioSciences and phase II iron chelator treatment

Friday, March 16, 2012 01:07 PM

Shire, the global specialty biopharmaceutical company, has signed an agreement to acquire San Carlos, Calif.-based FerroKin BioSciences for an upfront payment of $100 million.

More... »

Columbia, Weill Cornell join national effort to spur clinical trials in neurosciences

Friday, March 16, 2012 11:49 AM

The National Institute for Neurological Disorders and Stroke (NINDS) has selected Columbia University College of Physicians and Surgeons and Weill Cornell Medical College to participate in a new national effort to accelerate the development of therapies for people with neurological diseases.

More... »